A rare but severe stem cell transplant complication that often becomes fatal now has its first FDA-approved treatment, a therapy developed by biotechnology company Omeros. The Christmas ...
Growth and sustainability are often seen as competing priorities, as if progress in one must come at the expense of the other. Yet the truth is, growth can – and must – fuel ...
Sanofi is boosting its vaccine portfolio and pipeline through the acquisition of Dynavax Technologies, a $2.2 billion deal bringing assets that could give the company competitive ...
Ever since early February, when former FDA Commissioner Robert Califf publicly bemoaned the progress of precision medicine, I wanted to find out whether other people felt similarly ...
For a plaque psoriasis drug to succeed in a clinical trial, it doesn’t need to clear all of the redness and other signs of the inflammatory skin disease. But complete skin clearance is a ...
Enhertu, a targeted cancer therapy from partners AstraZeneca and Daiichi Sankyo, may now be used as a first-line treatment for advanced cases of breast cancer, making it the first new ...
Fresh off the acquisition of metabolic medicines developer Metsera, Pfizer is again turning to dealmaking to expand its obesity drug pipeline, this time picking up an experimental oral ...
Regeneron Pharmaceuticals is committing $150 million to begin an alliance on a Tessera Therapeutics gene-editing medicine nearing the clinic as a potential treatment for a rare disease ...
